MML Investors Services
CADL icon

MML Investors Services’s Candel Therapeutics CADL Stock Holding History

MML Investors Services’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
10,325
– – ﹤0.01% 3190
2026
Q1 		$50.6K Buy
+10,325
New +$56.2K ﹤0.01% 2936
2025
Q2 		– Sell
-48,419
Closed -$274K – 2812
2025
Q1 		$274K Sell
48,419
-816
-2% -$6.67K ﹤0.01% 2357
2024
Q4 		$427K Buy
49,235
+26,922
+121% +$159K ﹤0.01% 2017
2024
Q3 		$155K Sell
22,313
-51,063
-70% -$317K ﹤0.01% 2480
2024
Q2 		$455K Buy
+73,376
New +$551K ﹤0.01% 1846

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MML Investors Services's CADL Position: Q2 2026 in Review

MML Investors Services held its Candel Therapeutics (CADL) position steady in Q2 2026 at 10,325 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #3190.

MML Investors Services first reported a position in CADL in Q2 2024 and has held it in 6 quarters since. The position peaked at $455K in Q2 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • MML Investors Services held 10,325 shares of Candel Therapeutics worth $106K as of Q2 2026.
  • MML Investors Services left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #3190 holding.
  • MML Investors Services first reported a position in Candel Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • MML Investors Services's Candel Therapeutics position peaked at $455K in Q2 2024.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.